Mersana Therapeutics Company Leadership
MRSN Stock | USD 0.64 0.05 8.47% |
Mersana Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Mersana Therapeutics suggests that virtually all insiders are panicking. Mersana Therapeutics employs about 123 people. The company is managed by 14 executives with a total tenure of roughly 12 years, averaging almost 0.0 years of service per executive, having 8.79 employees per reported executive.
Ashish Mandelia President Vice President Controller |
Brian DeSchuytner President Senior Vice President - Finance and Product Strategy |
Mersana Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2025-01-16 | Timothy B Lowinger | Disposed 8048 @ 0.58 | View | ||
2025-01-14 | Timothy B Lowinger | Disposed 3483 @ 0.66 | View | ||
2024-10-28 | Mohan Bala | Disposed 1884 @ 1.9 | View | ||
2024-10-03 | Alejandra Carvajal | Disposed 5598 @ 1.96 | View | ||
2024-10-02 | Brian Deschuytner | Disposed 8089 @ 2 | View | ||
2024-09-12 | Martin H Jr. Huber | Disposed 50423 @ 1.76 | View |
Monitoring Mersana Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mersana |
Mersana Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1333) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to drop to -0.92. In addition to that, Return On Capital Employed is likely to drop to -0.99. At this time, Mersana Therapeutics' Other Current Assets are very stable compared to the past year. As of the 31st of January 2025, Fixed Asset Turnover is likely to grow to 5.34, while Total Assets are likely to drop about 180.4 M.As of the 31st of January 2025, Common Stock Shares Outstanding is likely to grow to about 140.2 M, though Net Loss is likely to grow to (174.6 M).
Mersana Therapeutics Workforce Comparison
Mersana Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,189. Mersana Therapeutics holds roughly 123 in number of employees claiming about 2.94% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.96) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.96. Mersana Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mersana Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mersana Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mersana Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ashish Mandelia over a week ago Disposition of 4166 shares by Ashish Mandelia of Mersana Therapeutics subject to Rule 16b-3 | ||
Mohan Bala over two weeks ago Disposition of 59 shares by Mohan Bala of Mersana Therapeutics at 0.58 subject to Rule 16b-3 | ||
Mohan Bala over two weeks ago Disposition of 3253 shares by Mohan Bala of Mersana Therapeutics at 0.66 subject to Rule 16b-3 | ||
Mohan Bala over two weeks ago Disposition of 8750 shares by Mohan Bala of Mersana Therapeutics subject to Rule 16b-3 | ||
Alleva Lawrence M over three weeks ago Acquisition by Alleva Lawrence M of 12521 shares of Mersana Therapeutics at 1.4 subject to Rule 16b-3 | ||
Nextech Crossover I Scsp over a month ago Insider Trading | ||
Ecor1 Capital, Llc over a month ago Acquisition by Ecor1 Capital, Llc of 8036688 shares of Mersana Therapeutics at 1.0E-4 subject to Rule 16b-3 | ||
Mohan Bala over two months ago Acquisition by Mohan Bala of 58333 shares of Mersana Therapeutics subject to Rule 16b-3 |
Mersana Therapeutics Notable Stakeholders
A Mersana Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mersana Therapeutics often face trade-offs trying to please all of them. Mersana Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mersana Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin MD | CEO President | Profile | |
MD Huber | CEO President | Profile | |
Ashish Mandelia | Vice President Controller | Profile | |
Brian DeSchuytner | Senior Vice President - Finance and Product Strategy | Profile | |
Alejandra JD | Secretary SVP | Profile | |
Chuck Miller | Senior Affairs | Profile | |
Carla Poulson | Chief Officer | Profile | |
Marc Damelin | Oncology, Biology | Profile | |
Jason Fredette | Senior Communications | Profile | |
Mohan Bala | Senior Officer | Profile | |
Tushar Misra | Senior Officer | Profile | |
Timothy Lowinger | Chief Scientific Officer | Profile | |
Anna MBA | CEO Pres | Profile | |
Mikhail Papisov | CoFounder | Profile |
About Mersana Therapeutics Management Performance
The success or failure of an entity such as Mersana Therapeutics often depends on how effective the management is. Mersana Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mersana management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mersana management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.87) | (0.92) | |
Return On Capital Employed | (0.95) | (0.99) | |
Return On Assets | (0.87) | (0.92) | |
Return On Equity | (5.35) | (5.08) |
Mersana Therapeutics Workforce Analysis
Traditionally, organizations such as Mersana Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mersana Therapeutics within its industry.Mersana Therapeutics Manpower Efficiency
Return on Mersana Therapeutics Manpower
Revenue Per Employee | 299.6K | |
Revenue Per Executive | 2.6M | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 12.3M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 10.7M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth 0.637 | Return On Assets | Return On Equity |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.